Even with MINT's mandatory steroid taper, inebilizumab still cut exacerbation and rescue therapy rates versus placebo, said ...

Precision medicine approaches for chronic obstructive pulmonary disease (COPD) are lagging, creating gaps in care and leaving ...

Sixteen weeks of dupilumab improved lesion severity scores 59.8% vs 15.2% with placebo in 94 adults with moderate-to-severe ...

Define the “last-mile equity gap” as the unmeasured distance between care delivery and patient comprehension, which can ...

In part 1 of an interview with The American Journal of Managed Care® ( AJMC®) at the Community Oncology Alliance (COA) Payer ...

Keith Kaye, MD, MPH, breaks down the institutional gaps, from antibiotic overuse to hand hygiene fatigue, that let ...

Christos Vaklavas, MD, discussed barriers limiting rural oncology access and challenges to adopting resource-intensive ...

Lalan Wilfong, MD, discusses how model assumptions, cohort design, and risk adjustment shape performance and accountability ...

Terminology shifts to “decompensated heart failure,” introducing an initial–stabilization–pre/postdischarge framework and ...

Biomarker testing remains a cornerstone of precision oncology, particularly for non–small cell lung cancer, yet obstacles ...

Enlicitide (Lipfendra; Merck), the first oral PCSK9 inhibitor, produced a low-density lipoprotein (LDL) cholesterol reduction of approximately 60% sustained through 52 weeks, alon ...

Francesca Polverino, MD, PhD, discusses COPD biomarkers, patient susceptibility, overtreatment risk, and the future of risk ...